TG Therapeutics Stock Income Statements

TG Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

TG Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2013-12-31	2013-09-30	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2007-12-31	2007-09-30	2007-08-06

revenue:
product revenue	138,843,000	119,655,000	107,347,000	83,297,000	72,596,000	50,488,000	43,137,000	25,068,000	16,036,000	7,765,000	647,750	56,000	556,000	1,978,000	2,283,000	1,992,000	1,507,000	755,000
license, milestone, royalty and other revenue	2,305,000	1,201,000	838,000	582,000	870,000	12,986,000
total revenue	141,148,000	120,856,000	108,185,000	83,879,000	73,466,000	63,474,000	43,971,000	165,815,000	16,074,000	7,803,000	676,250	94,000	594,000	2,016,000	1,092,000	2,030,000	1,545,000	793,000
yoy	92.13%	90.40%	146.04%	-49.41%	357.05%	713.46%	6402.18%	176298.94%	2606.06%	287.05%	-38.07%	-95.37%	-61.55%	154.22%
qoq	16.79%	11.71%	28.98%	14.17%	15.74%	44.35%	-73.48%	931.57%	106.00%	1053.86%	619.41%	-84.18%	-70.54%	84.62%	-46.21%	31.39%	94.83%

costs and expenses:
cost of revenue	18,938,000	15,541,000	15,399,000	9,341,000	8,304,000	5,441,000	7,854,000	3,509,000
gross profit	122,210,000	105,315,000	92,786,000	74,538,000	65,162,000	58,033,000	36,117,000	162,306,000
yoy	87.55%	81.47%	156.90%	-54.08%
qoq	16.04%	13.50%	24.48%	14.39%	12.28%	60.68%	-77.75%
gross margin %	86.58%	87.14%	85.77%	88.86%	88.70%	91.43%	82.14%	97.88%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
research and development:
noncash compensation	4,318,000	3,331,000	3,160,000	3,028,000	2,520,000	2,452,000	2,848,000	2,915,000	5,664,000	1,584,000	5,753,000	3,249,000	2,328,000	1,895,000	4,986,000	4,534,000	7,016,000	7,511,000	5,812,000	4,618,000	1,553,000	1,979,000	1,488,000	1,482,000	1,352,000	1,489,000	1,207,000	644,000	888,000	2,859,000	260,007	1,814,288	1,266,322	2,306,099	868,624	919,648	567,157	386,925	1,528,296	35,756	1,359,446	1,337,908	2,329,270	1,200,575	3,300,111	149,206	171,442
other research and development	27,464,000	43,031,000	20,714,000	17,110,000	15,036,000	30,270,000	14,601,000	11,838,000	22,458,000	14,286,000	23,882,000	17,552,000	24,546,000	46,147,000	57,660,000	47,433,000	37,855,000	55,583,000	37,149,000	45,846,000	34,896,000	34,043,000	29,455,000	56,503,000	31,414,000	30,896,000	51,069,000	32,754,000	34,812,000	32,159,000	25,736,101	25,334,762	25,439,477	20,375,794	21,414,723	20,878,108	12,966,574	11,230,415	13,725,926	11,538,246	9,902,214	8,279,431	12,807,504	8,352,154	2,336,771	3,606,385	3,138,119
total research and development	31,782,000	46,362,000	23,874,000	20,138,000	17,556,000	32,722,000	17,449,000	14,753,000	28,122,000	15,870,000	29,635,000	20,801,000	26,874,000	48,042,000	62,646,000	51,967,000	44,871,000	63,094,000	42,961,000	50,464,000	36,449,000	36,022,000	30,943,000	57,985,000	32,866,000	32,385,000	52,276,000	33,398,000	38,700,000	35,018,000	25,996,108	27,149,050	26,705,799	22,681,893	22,283,347	21,797,756	13,533,731	11,617,340	15,254,222	11,574,002	11,261,660	9,617,339	15,136,774	13,691,573	6,848,132	3,755,591	3,309,561
selling, general and administrative:
other selling, general and administrative	43,541,000	38,691,000	30,175,000	33,221,000	31,828,000	27,694,000	24,616,000	26,500,000	23,838,000	22,828,000	17,206,000	10,514,000	15,942,000	20,383,000	23,042,000	25,436,000	24,729,000	17,655,000
total selling, general and administrative	55,585,000	50,331,000	38,963,000	41,966,000	38,790,000	34,581,000	31,153,000	32,769,000	30,715,000	28,068,000	22,504,000	14,254,000	12,638,000	20,609,000	32,412,000	34,899,000	34,017,000	26,762,000
total costs and expenses	106,305,000	112,234,000	78,236,000	71,445,000	64,650,000	72,744,000	56,456,000	51,031,000	60,748,000	44,795,000	52,142,000	35,057,000	39,535,000	68,888,000	95,268,000	87,158,000	79,036,000	89,995,000	86,820,000	85,760,000	50,883,000	50,283,000	37,999,000	60,899,000	35,582,000	34,727,000	54,188,000	34,366,000	44,383,000	40,615,000	31,072,826	31,623,323	28,463,466	27,704,517	24,066,153	24,963,567	16,061,538	14,030,251	17,678,096	13,863,680	17,149,675	14,640,946	18,759,219	17,477,442	11,993,592	8,013,861	4,685,513
operating income	34,843,000	8,622,000	29,949,000	12,434,000	8,816,000	-9,270,000	-12,485,000	114,784,000	-44,674,000	-36,992,000	-52,062,000	-34,963,000	-38,941,000	-66,872,000	-92,947,000	-85,128,000	-77,492,000	-89,202,000	-86,782,000	-85,722,000	-50,845,000	-50,245,000	-37,961,000	-60,861,000	-35,544,000	-34,689,000	-54,150,000	-34,328,000	-44,345,000	-41,577,000	-31,034,731	-31,585,227	-28,425,371	-27,666,422	-24,028,058	-24,925,471	-16,023,443	-13,992,156	-17,640,001	-13,825,584	-17,111,580	-14,602,851	-18,721,124	-17,439,346	-11,955,497	-7,975,766	-4,647,417	-261,843	-322,906	-566,085	-61,322,150	-515,631	-525,091	-529,445	-59,445,344	-395,640	-477,260	-557,336		-44,466,120	-2,707,021	-45,141,536
yoy	295.22%	-193.01%	-339.88%	-89.17%	-119.73%	-74.94%	-76.02%	-428.30%	14.72%	-44.68%	-43.99%	-58.93%	-49.75%	-25.03%	7.10%	-0.69%	52.41%	77.53%	128.61%	40.85%	43.05%	44.84%	-29.90%	77.29%	-19.85%	-16.57%	74.48%	8.68%	56.00%	50.28%	29.16%	26.72%	77.40%	97.73%	36.21%	80.29%	-6.36%	-4.18%	-5.77%	-20.72%	43.13%	83.09%	302.83%	6560.23%	3602.47%	1308.93%	-92.42%	-49.22%	-38.50%	6.92%	3.16%	30.33%	10.02%	-5.00%		-99.11%	-82.37%	-98.77%
qoq	304.12%	-71.21%	140.86%	41.04%	-195.10%	-25.75%	-110.88%	-356.94%	20.77%	-28.95%	48.91%	-10.22%	-41.77%	-28.05%	9.18%	9.85%	-13.13%	2.79%	1.24%	68.59%	1.19%	32.36%	-37.63%	71.23%	2.46%	-35.94%	57.74%	-22.59%	6.66%	33.97%	-1.74%	11.12%	2.74%	15.14%	-3.60%	55.56%	14.52%	-20.68%	27.59%	-19.20%	17.18%	-22.00%	7.35%	45.87%	49.90%	71.62%	1674.89%	-18.91%	-42.96%	-99.08%	11792.64%	-1.80%	-0.82%	-99.11%	14925.11%	-17.10%	-14.37%			1542.62%	-94.00%
operating margin %	24.69%	7.13%	27.68%	14.82%	12.00%	-14.60%	-28.39%	69.22%	-277.93%	-474.07%	-7698.63%	-37194.68%	-6555.72%	-3317.06%	-8511.63%	-4193.50%	-5015.66%	-11248.68%
other income:
interest expense	6,716,000	6,757,000	7,061,000	10,832,000	3,977,000	2,288,000	2,431,000	3,713,000	3,627,000	2,844,000	2,862,000	1,648,000	3,017,000	2,664,000	1,079,000	1,038,000	1,623,000	1,898,000	1,291,000	1,610,000	2,228,000	1,201,000	1,899,000	1,537,000	1,077,000										168,674.75	211,538	220,756	242,405	242,026	246,527	246,526	237,657	234,787	234,787	234,787	178,004	240,530	1,165,078	428,210	289,598	234,388.75	349,562	351,215	236,777	99,174.5	136,738	134,510	125,450		25,559		26,033
other income	-2,793,000	-3,603,000	-2,565,000	-2,666,000	-1,712,000	-880,000	-890,000	-2,859,000	-691,000	-604,000	-1,930,000	-793,000	-1,448,000	-523,000	-688,000	-529,000	-618,000	-472,000	145,000	-169,000	-189,000	-330,000	-288,000	-468,000	-408,000	616,000	-24,000	-119,000	-14,000	96,000			-22,090	105,783	-360,160	-33,042
total other income	3,923,000	3,154,000	4,496,000	8,166,000	2,265,000	1,408,000	1,541,000	854,000	2,936,000	2,240,000	932,000	855,000	1,569,000	2,141,000	391,000	509,000	1,005,000	1,426,000	1,436,000	1,441,000	2,039,000	871,000	1,611,000	1,069,000	669,000	467,000	-290,000	-377,000	-203,000	-48,000	-174,964	-49,575	-72,287	61,087	-353,915	-94,444	-124,381	-143,494	-28,189	-169,668	-8,397	-25,116	75,305	11,823	30,933	-43,966.25	-91,222	289,896	2,659,633	-4,398,468	-933,591	-556,878	-2,375,427	1,103,724	-1,261,926	20,449	915,177	204,508		-774,772	-37,600	-790,105
net income before taxes	30,920,000	5,468,000	25,453,000	4,268,000	6,551,000	-10,678,000
income tax benefit	-2,733,000				328,000
net income	28,187,000	5,060,000	23,331,000	3,880,000	6,879,000	-10,707,000	-14,416,000	113,930,000	-47,610,000	-39,232,000	-52,994,000	-35,818,000	-40,510,000	-69,013,000	-93,338,000	-85,637,000	-78,497,000	-90,628,000	-88,218,000	-87,163,000	-52,884,000	-51,116,000	-39,572,000	-61,930,000	-36,213,000	-35,156,000	-53,860,000	-33,951,000	-44,142,000	-41,529,000	-30,859,767	-31,535,652	-28,353,084	-27,727,509	-13,644,687.75	-24,831,027	-15,899,062	-13,848,662	-17,611,812	-13,655,916	-17,103,183	-14,577,735						-551,739	-2,982,539	3,832,383	-60,388,559	41,247	1,850,336	-1,633,169	-58,183,418	-416,089	-1,392,437	-761,844		-43,691,348	-2,669,421	-44,351,431
yoy	309.75%	-147.26%	-261.84%	-96.59%	-114.45%	-72.71%	-72.80%	-418.08%	17.53%	-43.15%	-43.22%	-58.17%	-48.39%	-23.85%	5.80%	-1.75%	48.43%	77.30%	122.93%	40.74%	46.04%	45.40%	-26.53%	82.41%	-17.96%	-15.35%	74.53%	7.66%	55.69%	49.78%	126.17%	27.00%	78.33%	100.22%	-22.53%	81.83%	-7.04%	-5.00%										-1437.65%	-261.19%	-334.66%	3.79%	-109.91%	-232.88%	114.37%		-99.05%	-47.84%	-98.28%
qoq	457.06%	-78.31%	501.31%	-43.60%	-164.25%	-25.73%	-112.65%	-339.30%	21.36%	-25.97%	47.95%	-11.58%	-41.30%	-26.06%	8.99%	9.10%	-13.39%	2.73%	1.21%	64.82%	3.46%	29.17%	-36.10%	71.02%	3.01%	-34.73%	58.64%	-23.09%	6.29%	34.57%	-2.14%	11.22%	2.26%	103.21%	-45.05%	56.18%	14.81%	-21.37%	28.97%	-20.16%	17.32%							-81.50%	-177.82%	-106.35%	-146507.15%	-97.77%	-213.30%	-97.19%	13883.41%	-70.12%	82.77%			1536.74%	-93.98%
net income margin %	19.97%	4.19%	21.57%	4.63%	9.36%	-16.87%	-32.79%	68.71%	-296.19%	-502.78%	-7836.45%	-38104.26%	-6819.87%	-3423.26%	-8547.44%	-4218.57%	-5080.71%	-11428.50%
net income per common share:
basic	190	30	160	30	50		-100	800
diluted	170	30	150	20	40		-100	730
weighted-average shares of common stock outstanding
basic	146,739,833,000	146,677,783,000	145,317,418,000	145,102,479,000	144,727,482,000		141,955,112,000	142,871,227,000
diluted	162,559,404,000	162,769,202,000	160,336,051,000	160,714,388,000	159,423,571,000		148,508,465,000	155,871,749,000
income tax expense		408,000	22,250	388,000
income taxes						29,000
basic and diluted net income per common share						-70			-340	-280	-380	-260	-300	-510	-700	-650	-590	-690	-720	-730	-470	-480	-410	-690	-420	-430	-690	-430	-590	-590	-0.46	-0.48	-0.45	-0.52	-0.49	-0.5	-0.33	-0.28	-0.37	-0.28	-0.38	-0.35	-0.5	-0.51	-0.36	-0.155	-0.16
weighted-average shares used for eps calculation						146,209,213,000			141,503,738,000	140,312,269,000	135,411,258,000	135,327,035,000	134,779,904,000	134,400,500,000	132,222,753,000	132,353,119,000	132,072,996,000	131,898,626,000	115,333,693,000	119,176,336,000	112,353,414,000	105,461,892,000	88,368,844,000	89,667,979,000	86,800,017,000	81,174,301,000		78,221,069,000	74,256,348,000	70,636,970,000		65,079,128	63,288,269	53,157,851		49,203,277	48,769,948	48,908,278	45,646,414	47,946,309	45,320,637	41,088,752	34,068,926	34,188,108	32,985,130		27,684,802
license, milestone and other revenue							834,000	140,747,000
weighted-average shares outstanding:
basic	146,739,833,000	146,677,783,000	145,317,418,000	145,102,479,000	144,727,482,000		141,955,112,000	142,871,227,000
diluted	162,559,404,000	162,769,202,000	160,336,051,000	160,714,388,000	159,423,571,000		148,508,465,000	155,871,749,000
license revenue																			38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,095	38,096	38,095	38,095	38,095	38,096	38,095	38,095	38,095	38,096	38,095	38,095	38,095	38,096	38,095	38,095	38,096
cost of product revenue
noncash stock expense associated with in-licensing agreements
general and administrative:
other general and administrative																			16,150,000	11,584,000	8,617,000	5,172,000	2,924,000	2,321,000	2,311,000	1,949,000	1,661,000	1,785,000	2,308,000	2,119,000	1,766,747	1,398,438	1,534,261	1,333,268	1,322,831	1,251,421	1,446,567	1,100,871	1,095,126	1,085,400	1,004,475	1,004,487	913,279	889,872	706,725	662,728	550,639
total general and administrative																			43,859,000	35,296,000	14,434,000	14,261,000	7,056,000	2,914,000	2,716,000	2,342,000	1,912,000	968,000	5,683,000	6,597,000	5,076,718	4,474,273	1,757,667	5,022,624	1,782,806	3,165,811	2,527,807	2,412,911	2,423,874	2,289,678	5,888,015	5,023,607	3,622,445	3,785,869	5,145,460	1,460,670	1,375,952
other income :
noncash stock expense associated with in–licensing agreements																							25,000
non-cash stock expense associated with in–licensing agreements																									100,000		1,000,000		3,000,000
interest income																										-149,000	-266,000	-258,000	-189,000	-144,000	-120,422	-79,163	-50,197	-44,696	-57,576	-87,965	-92,629	-84,862	-64,993	-55,977	-31,551	-22,132	-16,741	-12,107	-12,727	-3,763.5	-12,375
other																															28,320.25	29,588
change in fair value of notes payable																																			-184,630	-184,975	-252,508	-301,037	-205,222	-360,218	-223,372	-240,641	-142,741	-210,857	-191,127	-218,206.75	-319,377
noncash stock expense associated with in-licensing agreement																																													1,211,250
noncash stock expense associated with in- licensing agreements																																											1,337,523.5	4,138,844
consolidated net income																																											-9,246,212	-17,451,169	-11,986,430	-5,663,852	-4,556,195
impairment of in-process research and development
income before income taxes																																														-5,663,852	-4,556,195
net income attributable to noncontrolling interest
net income attributable to tg therapeutics, inc. and subsidiaries																																														-3,703,589.5	-4,556,195
revenue
research and development																																																95,897	90,218	355,177	28,522,504	236,734	50,999	17,767	28,275,057	5,574	6,644	44,936		19,129,003	1,808,958
general and administrative																																																165,946	232,688	210,908	18,449,731	278,897	474,092	511,678	16,820,372	390,066	470,616	512,400		10,987,202	898,063
in-process research and development charge																																																														11,887,807
impairment of intangible assets																																																														1,248,230
loss on disposition of intangible assets																																																														1,213,878
total operating expenses																																																261,843	322,906	566,085	61,322,150	515,631	525,091	529,445	59,445,344	395,640	477,260	557,336		44,466,120	2,707,021	45,141,536
equity in losses of hedrin jv																																																							412,952	105,362	95,900	135,786
change in fair value of derivative liability																																																-2,100,898	2,231,746	-170,435	-674,225	-830,165
interest and other income																																																-196	-323	-143	-2,187,369	-76,275	-76,716	-75,314	-1,614,729	-63,873	-61,900	-126,728		-724,299	-37,600	-740,106
loss on early extinguishment of debt																																																1,225,912					159,070
realized gain on sale of marketable equity securities																																																														-76,032
preferred stock dividends																																																														-1,179,644
net income applicable to common shares																																																-551,739	-2,982,539	3,832,383	-61,568,204	41,247	1,850,336	-1,633,169	-59,363,063	-416,089	-1,392,437	-761,844		-44,870,992	-2,669,421	-45,531,075
net income per common share:
basic and diluted																																																-0.16	-1.15	0.03		0	0.02	-0.02	-0.01	-0.01	-0.02	-0.01		-0.038	-0.04
weighted-average shares of common stock outstanding:
basic and diluted																																																3,431,031	2,595,866	127,439,132		120,965,244	120,429,688	84,638,502		70,624,232	70,624,232	70,624,232			70,591,623
gain on nordic settlement																																																		-4,517,488
change in fair value of derivative																																																					-2,808,996	942,261	-228,819	-157,778	746,667	70,000
(including stock based compensation expense of
102,739, 98,302 and 631,462 for the three months
ended march 31, 2007, march 31, 2006 and for the
cumulative period from august 6, 2001 (inception) to
march 31, 2007, respectively)																																																														19,632,804
232,471, 213,610 and 1,379,247 for the three months
see accompanying notes to unaudited condensed consolidated financial statements.

We provide you with 20 years income statements for TG Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TG Therapeutics stock. Explore the full financial landscape of TG Therapeutics stock with our expertly curated income statements.

The information provided in this report about TG Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.